[go: up one dir, main page]

BRPI0503817A - complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada - Google Patents

complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada

Info

Publication number
BRPI0503817A
BRPI0503817A BRPI0503817-0A BRPI0503817A BRPI0503817A BR PI0503817 A BRPI0503817 A BR PI0503817A BR PI0503817 A BRPI0503817 A BR PI0503817A BR PI0503817 A BRPI0503817 A BR PI0503817A
Authority
BR
Brazil
Prior art keywords
immunogenic complex
present
silica
encapsulated
antigen
Prior art date
Application number
BRPI0503817-0A
Other languages
English (en)
Inventor
Ogari De Castro Pacheco
Osvaldo Augusto Brazil Es Anna
Lucildes Pita Mercuri
Jivaldo Do Rosario Matos
Marcia Carvalho De Abr Fantini
Original Assignee
Cristalia Prod Quimicos Farm
Fundacao De Amparo A Pesquisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Prod Quimicos Farm, Fundacao De Amparo A Pesquisa filed Critical Cristalia Prod Quimicos Farm
Priority to BRPI0503817-0A priority Critical patent/BRPI0503817A/pt
Priority to US12/066,489 priority patent/US8642258B2/en
Priority to ES06775036T priority patent/ES2423892T3/es
Priority to JP2008530281A priority patent/JP5091863B2/ja
Priority to CN2006800383996A priority patent/CN101287491B/zh
Priority to KR1020087007043A priority patent/KR101089400B1/ko
Priority to PCT/BR2006/000182 priority patent/WO2007030901A1/en
Priority to HK09102975.6A priority patent/HK1124791B/xx
Priority to CA2621373A priority patent/CA2621373C/en
Priority to EP06775036.4A priority patent/EP1942934B1/en
Publication of BRPI0503817A publication Critical patent/BRPI0503817A/pt
Priority to ZA200802277A priority patent/ZA200802277B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPLEXO IMUNOGêNICO FORMADO POR ANTìGENOS VACINAIS ENCAPSULADOS POR SìLICA MESOPOROSA NANOESTRUTURA A presente invenção refere-se a um produto dito "complexo imunogênico" que compreende um adjuvante caracterizado por partículas sólidas de sílica mesoporosa nanoestruturada altamente ordenada, preferentemente a sílica SBA-15, e antígenos vacinais de naturezas diversas encapsulados nos ditos adjuvantes. O complexo imunogênico da presente invenção permite a apresentação dos antígenos que o compõe aos linfócitos de maneira segura, gradual e prolongada que leva a uma memória imunológica mais eficiente, aumenta a imunogenicidade do antígeno e melhora a produção de anticorpos. Isto garante uma proteção imunológica eficiente com menores quantidades de antígenos e/ou menos repetições de doses vacinais. Alem disso as características do complexo imunogênico da presente invenção promovem efetiva indução de imunidade de maneira homogênea em indivíduos "bons e maus respondedores".
BRPI0503817-0A 2005-09-12 2005-09-12 complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada BRPI0503817A (pt)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BRPI0503817-0A BRPI0503817A (pt) 2005-09-12 2005-09-12 complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
KR1020087007043A KR101089400B1 (ko) 2005-09-12 2006-09-12 나노구조의 메소다공성 실리카에 의해 캡슐화된 백신항원에 의해 형성된 면역원 복합체
ES06775036T ES2423892T3 (es) 2005-09-12 2006-09-12 Complejo inmun�geno formado por ant�genos de vacuna encapsulados con s�lice mesoporosa nanoestructurada
JP2008530281A JP5091863B2 (ja) 2005-09-12 2006-09-12 ナノ構造のメソポーラスシリカに組み込まれたワクチン抗原からなる免疫原性複合体
CN2006800383996A CN101287491B (zh) 2005-09-12 2006-09-12 由使用纳米结构的中孔二氧化硅包囊的疫苗抗原形成的免疫原性复合物
US12/066,489 US8642258B2 (en) 2005-09-12 2006-09-12 Immunogenical complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
PCT/BR2006/000182 WO2007030901A1 (en) 2005-09-12 2006-09-12 Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
HK09102975.6A HK1124791B (en) 2005-09-12 2006-09-12 Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
CA2621373A CA2621373C (en) 2005-09-12 2006-09-12 Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
EP06775036.4A EP1942934B1 (en) 2005-09-12 2006-09-12 Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
ZA200802277A ZA200802277B (en) 2005-09-12 2008-03-10 Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0503817-0A BRPI0503817A (pt) 2005-09-12 2005-09-12 complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada

Publications (1)

Publication Number Publication Date
BRPI0503817A true BRPI0503817A (pt) 2007-05-15

Family

ID=37864579

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0503817-0A BRPI0503817A (pt) 2005-09-12 2005-09-12 complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada

Country Status (10)

Country Link
US (1) US8642258B2 (pt)
EP (1) EP1942934B1 (pt)
JP (1) JP5091863B2 (pt)
KR (1) KR101089400B1 (pt)
CN (1) CN101287491B (pt)
BR (1) BRPI0503817A (pt)
CA (1) CA2621373C (pt)
ES (1) ES2423892T3 (pt)
WO (1) WO2007030901A1 (pt)
ZA (1) ZA200802277B (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102896A1 (pt) * 2016-12-05 2018-06-14 Universidade Estadual De Campinas - Unicamp Vacina para haemophilus aegypus e uso

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0503817A (pt) 2005-09-12 2007-05-15 Cristalia Prod Quimicos Farm complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
EP2347774B1 (en) 2005-12-13 2017-07-26 The President and Fellows of Harvard College Scaffolds for cell transplantation
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US9012399B2 (en) 2008-05-30 2015-04-21 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
DE102008033175A1 (de) * 2008-07-15 2010-01-21 Merck Patent Gmbh Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung
JP2010083834A (ja) * 2008-10-01 2010-04-15 Naris Cosmetics Co Ltd アレルゲン不活性化剤、及びそれを含有する化粧料。
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
WO2011109834A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
JP6104806B2 (ja) 2010-10-06 2017-03-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
US10647959B2 (en) 2011-04-27 2020-05-12 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
WO2012149358A1 (en) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2012167230A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
CN103012594B (zh) * 2011-09-22 2015-09-02 中国农业科学院兰州兽医研究所 一种运载猪圆环病毒抗原表位蛋白的纳米载体及应用
JP5999639B2 (ja) * 2011-11-25 2016-09-28 国立研究開発法人産業技術総合研究所 免疫刺激因子担持微粒子
PT2838515T (pt) * 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
JP2015537029A (ja) 2012-11-14 2015-12-24 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物
WO2014165617A1 (en) * 2013-04-02 2014-10-09 Stc.Unm Mesoporous alum nanoparticles as universal platform for antigen adsorption, presentation, and delivery
JP6622203B2 (ja) * 2013-12-19 2019-12-18 ザ ユニバーシティー オブ クイーンズランド シリカベシクルの合成方法およびその使用
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
CN105267970A (zh) * 2015-01-08 2016-01-27 浙江大学 一种表面具有二氧化硅的热稳定疫苗及其制备方法
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
HK1249452A1 (zh) 2015-04-10 2018-11-02 President And Fellows Of Harvard College 免疫细胞捕获装置及其制备和使用方法
JP6868862B2 (ja) * 2015-08-31 2021-05-12 国立研究開発法人産業技術総合研究所 メソポーラスシリカ粒子
CN105597094A (zh) * 2015-12-31 2016-05-25 河南农业大学 猪传染性胃肠炎病毒纳米硅佐剂灭活疫苗及其制备方法
WO2017120504A1 (en) 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
CN109072197A (zh) 2016-02-06 2018-12-21 哈佛学院校长同事会 重塑造血巢以重建免疫
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CA3032505A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
GB2552704A (en) * 2016-08-04 2018-02-07 Univ Bath Biomolecule preservation
CN106727426A (zh) * 2016-12-08 2017-05-31 中国药科大学 一种用于口服蛋白免疫载体的制备方法
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
US12252708B2 (en) 2018-09-24 2025-03-18 Unm Rainforest Innovations Living mammalian cells modified with functional modular nanoparticles
WO2020176716A1 (en) 2019-02-28 2020-09-03 Brinker C Jeffrey Modular metal–organic polyhedra superassembly compositions
EP4034148A4 (en) 2019-09-23 2025-09-10 Harvard College BIOMATERIAL-BASED ANTIGEN-FREE VACCINE AND ITS USE
CN114377120B (zh) * 2022-01-10 2023-09-22 大连理工大学 一种以病毒样颗粒为模板的二氧化硅疫苗递送系统的构建及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057296A (en) 1990-12-10 1991-10-15 Mobil Oil Corp. Method for synthesizing mesoporous crystalline material
US5102643A (en) 1990-01-25 1992-04-07 Mobil Oil Corp. Composition of synthetic porous crystalline material, its synthesis
WO2001012221A1 (en) * 1999-08-16 2001-02-22 Henceforth Hibernia, Inc. Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them
DK2116257T3 (da) * 2000-08-09 2013-02-04 Alk Abello As Parenterale vaccineformuleringer og anvendelser deraf
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
CN1193818C (zh) * 2002-03-13 2005-03-23 华东理工大学 一种二氧化硅磁性微球及其制备方法
US20040005352A1 (en) * 2002-04-16 2004-01-08 Lopez Gabriel P. Biologically functionalized porous microspheres
JP2004083501A (ja) * 2002-08-28 2004-03-18 Toyota Central Res & Dev Lab Inc 安定化抗体とこれを利用する免疫反応法及び免疫反応装置
JP2004155745A (ja) * 2002-11-08 2004-06-03 Kumamoto Technology & Industry Foundation ペプチドおよびその利用
US20040101822A1 (en) * 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
JP2004321010A (ja) * 2003-04-21 2004-11-18 Japan Science & Technology Agency 新規レンサ球菌タンパク質抗原
US20060018966A1 (en) * 2003-07-22 2006-01-26 Lin Victor S Antimicrobial mesoporous silica nanoparticles
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
JP4429105B2 (ja) * 2003-08-19 2010-03-10 キヤノン株式会社 有機物固定化構造体及びその製造方法、ペプチド及びｄｎａ
BRPI0503817A (pt) 2005-09-12 2007-05-15 Cristalia Prod Quimicos Farm complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102896A1 (pt) * 2016-12-05 2018-06-14 Universidade Estadual De Campinas - Unicamp Vacina para haemophilus aegypus e uso

Also Published As

Publication number Publication date
EP1942934A1 (en) 2008-07-16
KR101089400B1 (ko) 2011-12-07
CN101287491A (zh) 2008-10-15
CN101287491B (zh) 2013-01-30
HK1124791A1 (en) 2009-07-24
EP1942934B1 (en) 2013-05-01
ZA200802277B (en) 2009-01-28
JP2009507859A (ja) 2009-02-26
US8642258B2 (en) 2014-02-04
WO2007030901A1 (en) 2007-03-22
ES2423892T3 (es) 2013-09-25
CA2621373C (en) 2014-05-27
US20080286371A1 (en) 2008-11-20
CA2621373A1 (en) 2007-03-22
KR20080047569A (ko) 2008-05-29
JP5091863B2 (ja) 2012-12-05

Similar Documents

Publication Publication Date Title
BRPI0503817A (pt) complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
García et al. An overview of adjuvant formulations and delivery systems
Puggioni et al. Monophosphoryl lipid A (MPL®)* promotes allergen‐induced immune deviation in favour of Th1 responses
Azmi et al. Recent progress in adjuvant discovery for peptide-based subunit vaccines
Alving et al. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
TW200722101A (en) Novel composition
Pfaar et al. Adjuvants for immunotherapy
Martiñón et al. Chemical and immunological characteristics of aluminum‐based, oil‐water emulsion, and bacterial‐origin adjuvants
Klimek et al. Clinical use of adjuvants in allergen-immunotherapy
EA200900024A1 (ru) Противогриппозная вакцина
ATE555808T1 (de) Impfstoffzusammensetzung mit einem synthetischen adjuvans
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
BRPI0206672B8 (pt) composição imunológica, vacina conjugada tetravalente e vacina meningocócica multivalente
KR20130112790A (ko) 백신 조성물
CY1112589T1 (el) Ανοσογονος συνθεση που περιεχει ανοσοενισχυτικο
WO2009143457A3 (en) Vaccine composition containing synthetic adjuvant
Pérez et al. New vaccines require potent adjuvants like AFPL1 and AFCo1
EP2455101A3 (en) Influenza vaccine with oil-in-water emulsion adjuvant
EP2481422A3 (en) Multiplex vaccines
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
JP2014531396A (ja) 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
Burakova et al. Food‐Grade Saponin Extract as an Emulsifier and Immunostimulant in Emulsion‐Based Subunit Vaccine for Pigs
BRPI0515334A (pt) uso de um antìgeno de plasmodium
GB2442408A (en) Vaccine adjuvants
Pérez et al. Natural Neisseria derive proteoliposome and cochleate as potent vaccine adjuvants

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/07/2017, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2479 DE 10-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.